Brain Tumor Awareness Month: Providing Hope Through Research With Matthew Hadfield, DO; Morana Vojnic, MD, MBA; and Jethro Hu, MD

In honor of Brain Tumor Awareness Month (#GoGrayInMay), Oncology Data Advisor Fellows Forum and Editorial Board members—Dr. Matthew Hadfield, Dr. Morana Vojnic, and Dr. Jethro Hu—sat down to share new and ongoing treatment directions and words of hope for patients who are diagnosed with brain tumors.

Watch the video to hear more about:

  • The challenges in precision medicine and targeted therapy for brain tumors
  • Updates from the INDIGO trial, investigating vorasidenib for patients with residual/recurrent grade 2 IDH1/2-mutated glioma
  • The importance of molecular profiling for providing more information to determine treatment
  • The future of immunotherapy, vaccine-based therapy, and chimeric antigen receptor (CAR) T-cell therapy for brain tumors
  • The need to revise eligibility criteria of brain tumor clinical trials in order to make treatments more accessible
  • The power of patient advocacy groups and brain tumor support groups for sharing knowledge
  • The first thing that each of the speakers tell patients who are diagnosed with glioblastoma and the words of hope that they share

“I don’t know exactly where the big breakthrough is going to come, but certainly there are a lot of immunotherapy, targeted therapy, and precision medicine approaches. Hopefully in the next generation of those approaches, we’ll be able to not just take the bare minimum of next-generation sequencing data, but we’ll be able to incorporate more data regarding the signaling involved in these tumors and understand how they evolve over time.” – Jethro Hu, MD

“It’s a very challenging but very exciting field, especially given that the future seems much brighter than the past. We still have a long way to go, but there is some exciting data and hopefully some hope that we can provide for our patients.” – Morana Vojnic, MD, MBA

About the Speakers

Matthew Hadfield, DO, is a Hematology/Oncology Fellow at Brown University/Legoretta Cancer Center in Providence, Rhode Island. Prior to fellowship, he completed his Internal Medicine Residency at the University of Connecticut in 2021. Dr. Hadfield’s research focuses on melanoma and early-phase clinical trials. To date, he has published numerous peer-reviewed articles and studies, and he has presented his research at multiple national and international meetings. His main areas of interest include early-phase drug development, novel immunotherapeutic combinations to overcome therapeutic resistance, and predictive biomarkers for immunotherapy toxicities.

Morana Vojnic, MD, MBA, is an Assistant Professor of Medicine in the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health and a Medical Oncologist at Lenox Hill Hospital, where she serves as Director of Oncologic Services in the Brain and Spine Metastases Program. She specializes in thoracic and neuro-oncology, with expertise in the treatment of lung cancer, mediastinal tumors, head and neck cancer, brain cancer, and metastatic lesions of the brain and spine. With a background in molecular genetics, Dr. Vojnic designs personalized treatment plans and protocols using targeted drugs, immunotherapy, and chemotherapy for the treatment of patients with these diseases.

Jethro Hu, MD, is a Neuro-Oncologist at Cedars-Sinai Cancer and an Associate Professor in the Departments of Medicine, Neurology, and Neurosurgery at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Hu specializes in the treatment of brain cancers, including glioma, glioblastoma, central nervous system (CNS) lymphoma, meningioma, and brain metastases. His research interests include the development of novel therapies and the impacts of diet on neuro-oncology outcomes.

CME ad

Related Articles

Responses

Your email address will not be published. Required fields are marked *